(4R,6S)-6-[(1E)-2-[2-(Cyclopropyl-d5)-4-(4-fluorophenyl)-3-quinolinyl]ethenyl]tetrahydro-4-hydroxy-2H-pyran-2-one; [4R-[4α,6β(E)]]-6-[2-[2-(Cyclopropyl-d5)-4- (4-fluorophenyl)-3-quinolinyl]ethenyl]tetrahydro-4-hydroxy-2H-pyran-2-one; NK 104-d5; NK 104-d5 (lactone); Nisvastatin-d5; P 872441-d5;
參考CAS號:
141750-63-2-unlabelled
分子式:
C??H??D?FNO?
外觀:
白色至淡黃色固體
熔點:
72-75°C
分子量:
408.48
儲存:
Hygroscopic, -20?C Freezer, Under Inert Atmosphere
溶解度:
Chloroform (Slightly), Ethyl Acetate (Slightly)
類別:
Standards; Chiral Molecules; Isotopic Labeled Analogues; Enzyme Activators and Inhibitors; Pharmaceutical/API Drug Impurities/Metabolites;
應用:
A labelled metabolite of Pitavastatin. Recent studies have shown that conversion between acid and lactone forms occurs in the body, drug-drug interaction should be considered on both acid and lactone forms. The inhibitory effects of statins on CYP metabolic activities and MDR1 transporting activity were investigated using human liver microsomes and MDR1-overexpressing LLC-GA5-COL150 cells.
?您的位置：
